The lancet oncology
-
The lancet oncology · Jan 2019
Comparative StudySurgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study.
Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival. ⋯ Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348).
-
The lancet oncology · Jan 2019
Randomized Controlled Trial Multicenter StudyLenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsistent between individual studies. Minimal data are available on the effect of maintenance lenalidomide in more aggressive disease states, such as patients with cytogenetic high-risk disease or patients ineligible for transplantation. We aimed to assess lenalidomide maintenance versus observation in patients with newly diagnosed multiple myeloma, including cytogenetic risk and transplantation status subgroup analyses. ⋯ Cancer Research UK, Celgene, Amgen, Merck, and Myeloma UK.
-
The lancet oncology · Jan 2019
Randomized Controlled Trial Multicenter StudyUse of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer. ⋯ National Cancer Institute, Korea Health Technology R&D Project, Novartis.